For instance, collective use of ipilimumab (targeting PD-1, an immune checkpoint receptor) and nivolumab (targeting CTLA-4, a co-stimulatory receptor) can strengthen the anti-tumor response in the treatment of melanoma [28], advanced renal cell carcinoma [29], and esophageal carcinoma [30]. The gene discussed is CTLA4; the disease is melanoma.